cKIT Mutation Screening Exons 9 11 13 17 AML Test sale cost 1500 AED
Mesoridazine Test sale cost 1900 AED Mesoridazine Test Cost 2,110 د.إ Original price was: 2,110 د.إ.1,900 د.إCurrent price is: 1,900 د.إ.
NUDT15 Gene Mutation Analysis Test sale cost 1500 AED NUDT15 Gene Mutation Analysis Test Cost 2,000 د.إ Original price was: 2,000 د.إ.1,500 د.إCurrent price is: 1,500 د.إ.
Sale!

cKIT Mutation Screening Exons 9 11 13 17 AML Test Cost

Original price was: 2,000 د.إ.Current price is: 1,500 د.إ.

-25%

The “cKIT Mutation Screening Exons 9, 11, 13, 17 AML Test” is a specialized diagnostic assessment conducted to detect mutations in specific exons (9, 11, 13, and 17) of the cKIT gene. These mutations are significant because they can be implicated in the development of Acute Myeloid Leukemia (AML), a type of cancer that affects the blood and bone marrow. Identifying mutations in these exons helps in understanding the genetic basis of the disease, which can influence treatment decisions and prognosis.

This test is performed using advanced molecular techniques to analyze the patient’s DNA for any alterations in the specified exons of the cKIT gene. It is crucial for patients diagnosed with or suspected to have AML, as it provides vital information that can guide personalized treatment strategies, potentially leading to better outcomes.

The test is available at DNA Labs UAE, a leading laboratory known for its state-of-the-art facilities and expertise in genetic testing. The cost of the test is set at 1500 AED, making it accessible to patients and healthcare providers in the region. By offering this test, DNA Labs UAE plays a crucial role in the early detection and management of AML, contributing to improved patient care and survival rates.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

cKIT Mutation Screening Exons 9 11 13 17 AML Test

Test Name: cKIT Mutation Screening Exons 9 11 13 17 AML Test

Components: EDTA Blood (2ml)

Price: 1500.0 AED

Sample Condition: Peripheral Blood

Report Delivery: 7-8 days

Method: Sanger Sequencing

Test Type: Genetics

Doctor: Gynecologist

Test Department:

Pre Test Information: cKIT Mutation Screening (Exons 9, 11, 13, 17) AML can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

cKIT mutation screening refers to the process of analyzing specific exons (exons 9, 11, 13, and 17) of the cKIT gene in patients with acute myeloid leukemia (AML). The cKIT gene, also known as CD117, encodes a receptor tyrosine kinase that plays a crucial role in cell growth and differentiation.

Mutations in the cKIT gene have been associated with various malignancies, including AML. These mutations can lead to abnormal activation of the cKIT receptor, resulting in uncontrolled cell proliferation and survival.

Screening for cKIT mutations in AML patients can help in several ways:

  1. Diagnosis: Identifying cKIT mutations can aid in confirming the diagnosis of AML and distinguishing it from other types of leukemia.
  2. Prognosis: Certain cKIT mutations have been linked to specific clinical outcomes in AML. For example, patients with certain cKIT mutations may have a worse prognosis or be more resistant to certain treatments.
  3. Treatment Selection: Some targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed to specifically inhibit the activity of mutated cKIT receptors. Identifying cKIT mutations can help guide treatment decisions and determine if a patient is a candidate for these targeted therapies.

The specific exons analyzed in cKIT mutation screening (exons 9, 11, 13, and 17) were chosen because they are known to harbor the most common mutations in the cKIT gene associated with AML. By analyzing these exons, clinicians can detect the presence of mutations that may be relevant for diagnosis, prognosis, and treatment decisions in AML patients.

Test Name cKIT Mutation Screening Exons 9 11 13 17 AML Test
Components EDTA Blood (2ml)
Price 1500.0 AED
Sample Condition Peripheral Blood
Report Delivery 7-8 days
Method Sanger Sequencing
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information cKIT Mutation Screening (Exons 9, 11, 13, 17) AML can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

cKIT mutation screening refers to the process of analyzing specific exons (exons 9, 11, 13, and 17) of the cKIT gene in patients with acute myeloid leukemia (AML). The cKIT gene, also known as CD117, encodes a receptor tyrosine kinase that plays a crucial role in cell growth and differentiation.

Mutations in the cKIT gene have been associated with various malignancies, including AML. These mutations can lead to abnormal activation of the cKIT receptor, resulting in uncontrolled cell proliferation and survival.

Screening for cKIT mutations in AML patients can help in several ways:

1. Diagnosis: Identifying cKIT mutations can aid in confirming the diagnosis of AML and distinguishing it from other types of leukemia.

2. Prognosis: Certain cKIT mutations have been linked to specific clinical outcomes in AML. For example, patients with certain cKIT mutations may have a worse prognosis or be more resistant to certain treatments.

3. Treatment selection: Some targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed to specifically inhibit the activity of mutated cKIT receptors. Identifying cKIT mutations can help guide treatment decisions and determine if a patient is a candidate for these targeted therapies.

The specific exons analyzed in cKIT mutation screening (exons 9, 11, 13, and 17) were chosen because they are known to harbor the most common mutations in the cKIT gene associated with AML. By analyzing these exons, clinicians can detect the presence of mutations that may be relevant for diagnosis, prognosis, and treatment decisions in AML patients.

SKU: TEST-5138 Category:

Related products